Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW842166 · 3 trials · 3 indications
The index consisted of 24 questions (5 for pain, 2 for stiffness and 17 for physical and composite functions). The visual analog scale (VAS; 0-100 millimeter \[mm\]) was utilized in this study and participants were asked to rate joint pain they had in last 24 hours in the 5 pain items. Participants were asked to rate pain while performing following activities: walking on a flat surface, going up or down stairs; at night while in bed; sitting or lying and standing upright. Higher score (100) indicates extreme pain and lower score (0) indicates no pain. It was assessed on Day 1 pre-dose (Baseline), Day 1 (1 hour post-dose) and Day 14 (2-4 hours post-dose). Change from Baseline was planned to be calculated by subtracting Baseline value from post-Baseline value. Due to the early termination of this study, no formal statistical analysis was performed. Only summarized data is available.
| Arm | Type | Description |
|---|---|---|
| Overall study | EXPERIMENTAL | overall study population |
| Name | Type | Description |
|---|---|---|
| GW842166 | DRUG | 100 mg once daily |
| Placebo | DRUG | once daily |
Inclusion Criteria: * Male or female patients, 50 to 80 years of age. * A female is eligible to participate in this study if she is of: a) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal (more than 1 year since last menst...
GW842166 is an investigational small molecule being studied for the treatment of pain, including osteoarthritis and knee osteoarthritis. It has been evaluated in clinical trials for dental pain following third molar tooth extraction and for osteoarthritis pain in adults.
GW842166 is a small molecule that targets the CB2 receptor, a component of the endocannabinoid system involved in pain modulation. By acting on this receptor, it is intended to provide analgesic effects for pain conditions such as osteoarthritis.
GW842166 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company has sponsored clinical trials to evaluate the drug's safety and efficacy in pain-related indications.
GW842166 is in Phase 2 clinical development. All three completed trials were Phase 2 studies, including one in dental pain and two in osteoarthritis-related pain. The drug remains investigational and has not been approved by regulatory authorities.
GW842166 has been studied in three completed Phase 2 trials: NCT00444769 for dental pain after third molar extraction, NCT00447486 for osteoarthritis knee pain, and NCT00479427 for osteoarthritis. These trials were conducted in European countries including Germany, Italy, the United Kingdom, Denmark, Spain, and Sweden.
GW842166 is a CB2 receptor agonist, and one of its clinical trials, NCT00479427, is titled 'A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis.' This indicates that GW842166 is a CB2-targeting compound, though it is not known by any other drug name.